Meta-Analysis of Ado-Trastuzumab Emtansine in Patients with HER2- Positive Advanced Metastatic Breast Cancer

Journal Title: Journal of Medical Science And clinical Research - Year 2014, Vol 2, Issue 5

Abstract

This study identifies and reviews randomized evidence to determine the effectiveness and safety of AdoTrastuzumab Emtansine in patients with advanced metastatic breast cancer. Cochrane Breast Cancer Group specialized register; Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL and WHO International Clinical Registry platform were searched using the appropriate search strategy. Either recurrent or newly diagnosed women with Metastatic Breast Cancer were included. Four randomized controlled trials with 1,350 patients estimated overall survival as 64.7% in TDM1 group versus 51.8% in non TDM1 group. EMILIA study reported improved progression free survival (PFS) by 5.8 months, Overall Response Rate (ORR) as 43.6% in TDM1 group vs. 30.8% control group and low adverse events by 16.2%. Hurvitz study reported PFS 5 months longer in T-DM1 group than in control group with stratified HR of 0.59;(95% CI, 0.36 to 0.97), ORR as 64.2% (TDM 1 group) vs. 58% in control group, low adverse events by 45.2%. Single arm phase II study BURRIS & KROP reported PFS as 4.6 and 6.9 months respectively, ORR 25.9% and 34.5% respectively, and adverse events as 15.2% and 55.4% respectively. Consistent favorable outcomes with the Ado-Trastuzumab Emtansine indicate its considerable efficacy and safety in the treatment of advanced metastatic breast cancer and promising drug in combating mortality with breast cancer.

Authors and Affiliations

Dr Rajat Rana

Keywords

Related Articles

A study of use of Tunica Vaginalis flap in anterior urethral reconstruction

Hypospadias is the most common congenital anomaly of penis [1]. Surgical correction of proximal hypospadias is a technically challenging. Such surgeries are associated with maximum number of failures and results in cripp...

RBC is most and Lymphocyte Least Commonly Effected Hematological Cell in for Acute Aluminium Phosphide Poisoning (AALPP) Patients

Aims & Objectives: Exclude the EDTA induced storage artifacts .Identify and excludes the misinterpretation of peripheral blood smears examination. Identify the EDTA induced RBC & WBC morphological storage artifacts. Iden...

Role of Life Style Factors with Respect to Semen Quality and ART

One of the most painful problems of marital life is infertility. There are various causes of infertility such as endometriosis, ovulatory disorder, chromosomal abnormalities, semen quality and idiopathic infertility. The...

An Open Label, Prospective, Single Center Study to Evaluate the Efficacy of Methyldopa & labetalol in Treatment of Patients with Pregnancy-induced hypertension

Background: Pregnancy-induced hypertension is associated with various adverse fetal and maternal outcomes. The use of anti-hypertensive drugs in pregnancy is controversial. We conducted a prospective study to evaluate th...

Comparison of Obstructive Sleep Apnea Characteristics in Obese and NonObese Subjects by Anthropometric and Polysomnographic Data

Objective: To compare the anthropometric and polysomnographic data between obese and non-obese subjects with obstructive sleep apnea (OSA). Materials and Methods: A prospective parallel group comparative study was conduc...

Download PDF file
  • EP ID EP205926
  • DOI -
  • Views 108
  • Downloads 0

How To Cite

Dr Rajat Rana (2014). Meta-Analysis of Ado-Trastuzumab Emtansine in Patients with HER2- Positive Advanced Metastatic Breast Cancer. Journal of Medical Science And clinical Research, 2(5), 1222-1234. https://europub.co.uk/articles/-A-205926